Taysha Gene Therapies (TSHA) Non-Current Deffered Revenue (2023)
Taysha Gene Therapies (TSHA) posted Non-Current Deffered Revenue of $3.0 million for Q3 2023, down 51.61% sequentially from $6.2 million in Q2 2023.
Taysha Gene Therapies (TSHA) Non-Current Deffered Revenue (2023) Analysis & Trends
Taysha Gene Therapies has reported Non-Current Deffered Revenue for 1 years, with the latest figure at $3.0 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 3.00 Mn |
| Jun 30, 2023 | 6.20 Mn |